Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06758700 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 5, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Jul 31, 2025 to Jun 30, 2026
    • Study completion date: Dec 31, 2025 to Dec 31, 2026
    • Start date changed from estimate of Jan 7, 2025 to Feb 7, 2025
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.
Trial Details
NCT Number NCT06758700
Lead Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Collaborators: CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD
Conditions
(from sponsor)		 Extensive-stage Small Cell Lung Cancer (ES-SCLC), Thoracic Neoplasms, Lung Neoplasms, Lung Diseases
Related terms Lung Diseases, Lung Neoplasms, Small Cell Lung Carcinoma, Thoracic Neoplasms
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov